No Data
No Data
Celularity Granted European Patent EP3957315 For Treatment Of Diabetic Peripheral Neuropathy Using Placental Cells
Celularity Granted European Patent EP3957315 For Treatment Of Diabetic Peripheral Neuropathy Using Placental Cells
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced
Celularity Inc. to Host Investor and Analyst Research & Development Day
FLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial
Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024
Celularity Inc. (Nasdaq: CELU) today announced that its abstract entitled "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" was accepted by the Orthopedic Research Society (ORS) Tendon Conference, which will be held from May 30 - June 1, 2024 at the Mayo Clinic in Rochester, MN.
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
Expects the First Quarter of 2024 will be the 4th consecutive quarter of both sequential and quarter-on-quarter net sales growth Implements plan to reduce 2024 selling, general & administrative expens